Introduction
============

Asthma is airway hyperreactivity caused by inflammations. Patients with this disease exhibit symptoms such as wheezing, cough, chest tightness, dyspnea and other major symptoms ([@b1-etm-0-0-5997],[@b2-etm-0-0-5997]). In the United States, asthma is the most common cause of hospitalization in the emergency departments ([@b3-etm-0-0-5997]). According to the survey data in 2010 from the National Center for Health, 80,000 children were diagnosed with asthma at the age of 6 years or below ([@b4-etm-0-0-5997]).

A number of epidemiological studies have revealed that 25-hydroxyvitamin D \[25-(OH)D\] deficiency is associated with many diseases, especially with the occurrence of asthma symptoms ([@b5-etm-0-0-5997],[@b6-etm-0-0-5997]). Moreover, asthma has a significant correlation with inflammatory factors. This study assessed the potential relationship between 25-(OH)D level and inflammatory factors in children with asthma attack.

Patients and methods
====================

### Clinical data

A total of 60 child patients, who were admitted and treated in the Pediatric Department of the Affiliated Children\'sHospital of Xuzhou Medical University (Xuzhou, China) from March 2015 to March 2017 during their asthma attack were selected as the observation group. There were 29 boys and 31 girls, with an average age of 4.3±1.4 years. The children were diagnosed according to the Global Initiative for Asthma (GINA) criteria. This study was approved by the Ethics Committee of the Affiliated Children\'s Hospital of Xuzhou Medical University, and informed consent was obtained from patients and their families. The serum 25-(OH)D levels of the children were detected, with 14.30 ng/ml as the median level. Children with a 25-(OH)D level \>14.30 ng/ml were included in the high 25-(OH)D group (n=28), and those with a 25-(OH)D level \<14.30 ng/ml were included in the low 25-(OH)D group (n=32). In addition, 30 healthy children were recruited as the control group. There was no statistically significant difference for factors including age, sex, body mass index (BMI) and allergic conditions of the children between the two subgroups of the observation group, and data were comparable ([Table I](#tI-etm-0-0-5997){ref-type="table"}).

### Treatment methods

The children in the observation group received GINA treatment protocols ([@b7-etm-0-0-5997]). The appropriate treatment protocol was selected for each child in accordance with the control of asthma.

Index detections
----------------

### Examination of 25-(OH)D and biochemical indexes

Prior to the study commencing, fasting venous blood (10 ml) of the observation and control groups was collected in an anticoagulant tube containing EDTA. Following centrifugation for 10 min at 3,480 × g at 4°C, the serum 25-(OH)D level in the children was examined using ELISA. An automatic hematology analyzer (LH755; Beckman Coulter Biomedical GmbH, Munich, Germany) was utilized to detect the quantities of leukocytes, neutrophils, lymphocytes and eosinophils. The contents of immunoglobulin G (IgG), immunoglobulin A (IgA) and immunoglobulin M (IgM) were measured using immune scatter turbidimetry, Behring Nephelometer (BN) specific protein analyzer (CSL Behring, Pensylvania, PA, USA).

Blood of the children (10 ml) in the observation group was drawn at 8 a.m. on day 1, 3 and 7 after treatment, respectively; ELISA was performed to detect the levels of interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α) (cat. nos. ab46042 and ab181421; Abcam, Cambridge, MA, USA) in the serum.

### Measurement of pulmonary functions

Before the treatment, and on day 1, 3 and 7 after treatment, the RSFJ900 pulmonary function detector (RSDQ; Chongqing, China) was used to measure the forced expiratory volume in 1.0 sec (FEV1.0), peak expiratory flow (PEF), ratio of time to reach peak tidal expiratory flow to total expiratory time (TPTEF/TE) and ratio of volume to PEF and expiratory volume (VPEF/VE).

### Statistical analysis

The GraphPad Prism software Version 5.01 (GraphPad Software, Inc., La Jolla, CA, USA) was utilized for statistical analysis. When measurement data were presented as false, the Chi-square test was performed. Analysis of variance (ANOVA) was used for comparisons of differences among multiple groups, and Tukey test was used as post hoc test, and paired t-test was used for analysis on differences between the two groups. Pearson\'s correlation analysis was utilized to investigate the correlations of the levels of 25-(OH)D, IL-6 and TNF-α with the changes in pulmonary function indexes. Linear regression analysis was applied to analyze the correlation of 25-(OH)D with IL-6 and TNF-α. P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### Comparisons of patients general information

As shown in [Table I](#tI-etm-0-0-5997){ref-type="table"}, there were no statistically significant differences in age, sex, BMI and allergic conditions of the asthmatic children between the high and low 25-(OH)D groups (P\>0.05). However, the number of allergic patients in the observation group was significantly greater than that in the control group (P\<0.05).

### Correlation of serum 25-(OH)D with biochemical indexes

The quantities of leukocytes, neutrophils and eosinophils in patients in the high 25-(OH)D group were lower than those in the low 25-(OH)D group (P\<0.05). The quantities of leukocytes, neutrophils and eosinophils in patients in the observation group were significantly increased compared with those in the control group (P\<0.05) ([Table II](#tII-etm-0-0-5997){ref-type="table"}).

### Correlation of serum 25-(OH)D with humoral immunity

The levels of IgG, IgA and IgM in the low and high 25-(OH)D groups were significantly higher than those in the control group (P\<0.05). Moreover, the levels of immunologic factors in the low 25-(OH)D group were elevated compared with those in the high 25-(OH)D group (P\<0.05) ([Table III](#tIII-etm-0-0-5997){ref-type="table"}).

### Variations in serum TNF-α and IL-6 contents in the three groups of children

As shown in [Fig. 1](#f1-etm-0-0-5997){ref-type="fig"}, at the time of the first visit and during 7 days of treatment, the contents of serum IL-6 and TNF-α in asthmatic children of both the high and low 25-(OH)D groups were significantly higher than those of the normal control group (P\<0.05) with decreasing tendency. At 3 and 7 days after treatment, the serum IL-6 and TNF-α in the high 25-(OH)D group was lower compared with that in the low 25-(OH)D group (P\<0.05).

### Variations in pulmonary function indexes

The pulmonary functions of the children with acute attacks in the observation group were monitored, at the time of the visit, as well as on day 1, 3 and 7 after treatment, respectively. The results ([Table IV](#tIV-etm-0-0-5997){ref-type="table"}) indicated that the pulmonary functions in the low 25-(OH)D group were improved on day 3 after treatment, which was manifested as increased PEF, TPTEF/TE and VPEF/VE compared with those at the time of the visit. However, those indexes in the high 25-(OH)D group were improved on day 1 after treatment, which was manifested as increases in TPTEF/TE and VPEF/VE compared with those at the time of the visit (P\<0.05). Moreover, the treatment effect in the high 25-(OH)D group was better than that in the low 25-(OH)D group (P\<0.05).

### Correlations of 25-(OH)D, IL-6 and TNF-α levels with the changes in the pulmonary function indexes in asthmatic children

Pearson\'s correlation analysis was conducted for the levels of 25-(OH)D, IL-6 and TNF-α as well as the pulmonary function indexes in asthmatic children on day 7 after treatment. The results ([Table V](#tV-etm-0-0-5997){ref-type="table"}) showed that 25-(OH)D had a positive correlation with the pulmonary function indexes (P\<0.05), while TNF-α and IL-6 were negatively associated with the pulmonary function indexes (P\<0.05).

### Correlation analyses of 25-(OH)D with IL-6 and TNF-α in asthmatic children

Correlation analysis was conducted for the levels of serum 25-(OH)D, TNF-α and IL-6 in asthmatic children on day 7 after treatment. As shown in [Table VI](#tVI-etm-0-0-5997){ref-type="table"}, the serum 25-(OH)D level in asthmatic children was negatively associated with the levels of inflammatory factors TNF-α and IL-6 (P\<0.05).

Discussion
==========

Previous findings have shown that 25-(OH)D is a positive regulatory factor for innate and adaptive immune systems, which can regulate various immune cells, such as monocytes, macrophages, lymphocytes and epithelial cells ([@b7-etm-0-0-5997],[@b8-etm-0-0-5997]). In addition, 25-(OH)D can influence pulmonary functions by mediating the macrophages ([@b9-etm-0-0-5997]). Recent clinical studies have indicated that high-level 25-(OH)D is associated with good pulmonary functions, which can ameliorate the glucocorticoid response ([@b10-etm-0-0-5997]). It is known that 25-(OH)D deficiency is prevalent in child patients with mild to moderate persistent asthma, accompanied with the possibility of serious deterioration ([@b11-etm-0-0-5997]). Epidemiological studies have revealed that intake of VitD during pregnancy can lower the incidence rate of asthma in children ([@b12-etm-0-0-5997]). According to the suggestions of the National Center for Health, the ideal level of serum 25-(OH)D in healthy children is ≥30--40 ng/ml (75--100 nmol/l) ([@b13-etm-0-0-5997]). In the present study, it was found that the overall level of serum 25-(OH)D in asthmatic children was lower than that in the healthy controls. Detection of the pulmonary function indexes suggested that the pulmonary functions in the low 25-(OH)D group were improved at 3 days after treatment, while those in the high 25-(OH)D group were improved at 1 day after the treatment. In addition, the serum 25-(OH)D level had a positive correlation with pulmonary functions.

Asthma and airway inflammation are triggered by cytokines associated with T helper cell type 2, such as IL-4, IL-6 and IL-13 ([@b14-etm-0-0-5997]). In particular, IL-6 and IL-13 play important roles in the development of airway hyperreactivity ([@b15-etm-0-0-5997]). Moreover, the synergistic effects between the synthesis of specific immunoglobulin E and airway remodeling can lead to the formation of IL-6 receptor α-subunit, further inducing the occurrence of inflammations ([@b16-etm-0-0-5997],[@b17-etm-0-0-5997]). The research by Hinks *et al* ([@b18-etm-0-0-5997]) revealed that the increased TNF-α, IL-6 and IL-13 levels can obviously induce the occurrence of asthma and skin inflammations in the animal models. In addition, 25-(OH)D has the function of immunoregulation and host defense in addition to its influence on calcium and skeletal balance. Simpson *et al* found that 25-(OH)D can overcome the glucocorticoid response in patients with severe asthma by virtue of IL-10, which is an immunologic factor for cluster of differentiation 4 + T cell expressions ([@b19-etm-0-0-5997]). In addition, 25-(OH)D has a negative correlation with the severity of allergy and asthma, including a number of eosinophils, markers of serum IgE level and TNF-α level ([@b20-etm-0-0-5997],[@b21-etm-0-0-5997]).

In the present study, the quantities of leukocytes, neutrophils and eosinophils in patients were increased compared with those in the control group, and the indexes in the high 25-(OH)D group were lower than those in low 25-(OH)D group. However, there was no difference in lymphocytes between the two groups, which may owing to a relatively small number of participants in the two groups. The Pearson\'s correlation analysis revealed that the 25-(OH)D level had a positive correlation with the pulmonary function indexes. By contrast, the inflammatory factors TNF-α and IL-6 were negatively asociated with the pulmonary function indexes.

In conclusion, findings of the present study have shown that the level of 25-(OH)D was decreased in children suffering from asthma attack, which was associated with the inflammatory mediators, IL-6 and TNF-α, as well as pulmonary functions. Therefore, the level of 25-(OH)D can be employed as an indicator for the prevention and control of childhood asthma.
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###### 

Comparisons of patients general clinical information.

                                                                                             Observation group (n=60)                        
  --------------------- ------------ ------------------------------------------------------- -------------------------- ------------ ------- -------
  Age (years)           5.89±0.82    4.3±1.4                                                 4.2±1.1                    4.5±1.5      1.23    0.437
  Sex (male/total)      14/30        29/60                                                   17/32                      12/28        1.983   0.130
  BMI                   20.31±1.06   20.83±1.28                                              21.08±1.43                 20.65±1.25   1.534   0.582
  Allergy (yes/total)   0/30         11 (60)^[a](#tfn2-etm-0-0-5997){ref-type="table-fn"}^   6/32                       5/28         2.943   0.075

Compared to that in the control group

P\<0.05. 25-(OH)D, 25-hydroxyvitamin D; BMI, body mass index.

###### 

Correlation of serum 25-(OH)D with biochemical indexes in child patients.

                                                                                             Observation group (n=60)                                                                                                    
  -------------------- ----------- --------------------------------------------------------- --------------------------------------------------------- --------------------------------------------------------- ------- -------
  No. of leukocytes    5.89±0.82   7.23±2.18^[b](#tfn5-etm-0-0-5997){ref-type="table-fn"}^   8.21±2.71^[c](#tfn6-etm-0-0-5997){ref-type="table-fn"}^   6.67±1.59^[c](#tfn6-etm-0-0-5997){ref-type="table-fn"}^   2.034   0.362
  No. of neutrophils   3.32±0.56   4.01±1.71^[a](#tfn4-etm-0-0-5997){ref-type="table-fn"}^   5.74±2.13^[c](#tfn6-etm-0-0-5997){ref-type="table-fn"}^   3.68±1.27^[e](#tfn8-etm-0-0-5997){ref-type="table-fn"}^   2.851   0.048
  No. of lymphocytes   1.87±0.58   2.18±0.94                                                 2.28±1.11                                                 2.11±0.81                                                 1.328   0.382
  No. of eosinophils   0.15±0.09   0.47±0.43^[b](#tfn5-etm-0-0-5997){ref-type="table-fn"}^   0.49±0.53^[d](#tfn7-etm-0-0-5997){ref-type="table-fn"}^   0.40±0.30^[d](#tfn7-etm-0-0-5997){ref-type="table-fn"}^   1.284   0.321

The child patients in the observation group compared to those in the control group.

P\<0.05

P\<0.01, compared to that in the control group

P\<0.05

P\<0.01, compared to that in the low 25-(OH)D group

P\<0.05. 25-(OH)D, 25-hydroxyvitamin D.

###### 

Correlation of serum 25-(OH)D level with immunologic factors (mean ± SD, µg/ml).

  Groups     No.   IgG                                                                                                       IgA                                                                                                      IgM
  ---------- ----- --------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------
  Control    30    8.34±1.88                                                                                                 1.58±0.51                                                                                                1.22±0.35
  Low 25-    32    29.06±3.65^[a](#tfn10-etm-0-0-5997){ref-type="table-fn"}^                                                 11.62±2.01^[a](#tfn10-etm-0-0-5997){ref-type="table-fn"}^                                                13.54±1.62^[a](#tfn10-etm-0-0-5997){ref-type="table-fn"}^
  (OH)D                                                                                                                                                                                                                               
  High 25-   28    17.28±2.34^[a](#tfn10-etm-0-0-5997){ref-type="table-fn"},[b](#tfn11-etm-0-0-5997){ref-type="table-fn"}^   6.34±1.25^[a](#tfn10-etm-0-0-5997){ref-type="table-fn"},[b](#tfn11-etm-0-0-5997){ref-type="table-fn"}^   5.67±0.84^[a](#tfn10-etm-0-0-5997){ref-type="table-fn"},[b](#tfn11-etm-0-0-5997){ref-type="table-fn"}^
  (OH)D                                                                                                                                                                                                                               

Comparison with that in the control group

P\<0.05; compared with that in the low 25-(OH)D group

P\<0.05. 25-(OH)D, 25-hydroxyvitamin D; SD, standard deviation.

###### 

Variations in pulmonary function indexes of patients before and after treatment.

  Groups          Time                     No.   FEV1.0 (l)                                                                                               PEF (l/min)                                                                                              TPTEF/TE                                                                                                  VPEF/VE
  --------------- ------------------------ ----- -------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------
  Control                                  30    3.92±0.21                                                                                                10.21±1.85                                                                                               32.43±2.36                                                                                                33.87±2.26
  Low 25-(OH)D    At the time of visit     32    2.03±0.24                                                                                                3.02±0.57                                                                                                13.15±1.32                                                                                                15.25±1.11
                  1 day after treatment          2.15±0.31                                                                                                3.86±0.84                                                                                                14.76±1.60                                                                                                16.32±1.52
                  3 days after treatment         2.58±0.54                                                                                                4.53±1.05^[a](#tfn13-etm-0-0-5997){ref-type="table-fn"}^                                                 17.05±1.72^[a](#tfn13-etm-0-0-5997){ref-type="table-fn"}^                                                 18.05±1.87^[a](#tfn13-etm-0-0-5997){ref-type="table-fn"}^
                  7 days after treatment         2.74±0.38^[a](#tfn13-etm-0-0-5997){ref-type="table-fn"}^                                                 5.29±1.54^[a](#tfn13-etm-0-0-5997){ref-type="table-fn"}^                                                 22.53±2.04^[b](#tfn14-etm-0-0-5997){ref-type="table-fn"}^                                                 22.35±2.43^[a](#tfn13-etm-0-0-5997){ref-type="table-fn"}^
  High 25-(OH)D   At the time of visit     28    2.08±0.17                                                                                                3.30±0.66                                                                                                12.53±1.51                                                                                                19.65±1.84^[a](#tfn13-etm-0-0-5997){ref-type="table-fn"},[c](#tfn15-etm-0-0-5997){ref-type="table-fn"}^
                  1 day after treatment          2.26±0.30                                                                                                4.01±0.82                                                                                                17.94±2.73^[a](#tfn13-etm-0-0-5997){ref-type="table-fn"}^                                                 19.65±1.84^[a](#tfn13-etm-0-0-5997){ref-type="table-fn"},[c](#tfn15-etm-0-0-5997){ref-type="table-fn"}^
                  3 days after treatment         3.01±0.25^[a](#tfn13-etm-0-0-5997){ref-type="table-fn"},[c](#tfn15-etm-0-0-5997){ref-type="table-fn"}^   5.84±1.25^[a](#tfn13-etm-0-0-5997){ref-type="table-fn"},[c](#tfn15-etm-0-0-5997){ref-type="table-fn"}^   24.62±2.94^[a](#tfn13-etm-0-0-5997){ref-type="table-fn"},[c](#tfn15-etm-0-0-5997){ref-type="table-fn"}^   24.46±3.85^[a](#tfn13-etm-0-0-5997){ref-type="table-fn"},[c](#tfn15-etm-0-0-5997){ref-type="table-fn"}^
                  7 days after treatment         3.54±0.37^[a](#tfn13-etm-0-0-5997){ref-type="table-fn"},[c](#tfn15-etm-0-0-5997){ref-type="table-fn"}^   6.92±1.07^[b](#tfn14-etm-0-0-5997){ref-type="table-fn"},[c](#tfn15-etm-0-0-5997){ref-type="table-fn"}^   28.68±3.51^[a](#tfn13-etm-0-0-5997){ref-type="table-fn"},[c](#tfn15-etm-0-0-5997){ref-type="table-fn"}^   30.01±3.94^[a](#tfn13-etm-0-0-5997){ref-type="table-fn"},[c](#tfn15-etm-0-0-5997){ref-type="table-fn"}^

Compared with that at the time of visit

P\<0.05

P\<0.01; compared with that in the low 25-(OH)D group

P\<0.05. PEF, peak expiratory flow, TPTEF/TE, ratio of time to reach peak tidal expiratory flow to total expiratory time; VPEF/VE, ratio of volume to PEF and expiratory volume; FEV1.0, forced expiratory volume in 1.0 sec.

###### 

Correlation analyses of levels of 25-(OH)D, IL-6 and TNF-α with pulmonary function indexes in asthmatic children.

             25-(OH)D   TNF-α    IL-6                       
  ---------- ---------- -------- -------- -------- -------- --------
  FEV1.0     0.763      \<0.05   −0.693   \<0.05   −0.668   \<0.05
  PEF        0.618      \<0.05   −0.635   \<0.05   −0.775   \<0.05
  TPTEF/TE   0.821      \<0.05   −0.743   \<0.05   −0.612   \<0.05
  VPEF/VE    0.714      \<0.05   −0.644   \<0.05   −0.603   \<0.05

25-(OH)D, 25-hydroxyvitamin D; TNF-α, tumor necrosis factor-α; IL-6, interleukin-6; PEF, peak expiratory flow, TPTEF/TE, ratio of time to reach peak tidal expiratory flow to total expiratory time; VPEF/VE, ratio of volume to PEF and expiratory volume; FEV1.0, forced expiratory volume in 1.0 sec.

###### 

Regression analyses on 25-(OH)D, IL-6 and TNF-α in asthmatic children.

  Inflammatory factor   Regression coefficient   t-value   P-value
  --------------------- ------------------------ --------- ---------
  TNF-α                 −1.42                    2.76      \<0.05
  IL-6                  −1.88                    3.04      \<0.05

TNF-α, tumor necrosis factor-α; IL-6, interleukin-6.

[^1]: Contributed equally
